CoChat

Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non‐alcoholic fatty liver disease: A randomized trial

Open access
Feng, Wen‐Huan, Bi, Yan, Li, Ping, Yin, Ting‐Ting, Gao, Cai‐Xia, Shen, Shan‐Mei, Gao, Li‐Jun, Yang, Dong‐Hui, Zhu, Da‐Long · 2019 · Journal of Diabetes Investigation
Cited by 139

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Aims/Introduction: To compare the effects of gliclazide, liraglutide and metformin on body composition in patients with type 2 diabetes mellitus with non‐alcoholic fatty liver disease. Materials and Methods: A total of 85 patients were randomly allocated to receive gliclazide (n = 27), liraglutide (n = 29) or metformin (n = 29) monotherapy for 24 weeks. Body composition was measured using dual‐energy X‐ray absorptiometry. Results: Liraglutide and metformin reduced total, trunk, limb, android and gynoid fat mass; this also led to weight reduction. However, gliclazide treatment produced no significant changes in weight or fat mass, likely because reductions in fat mass were concomitant with increases in lean tissue mass. Blood glucose concentrations and glycated hemoglobin levels improved in all treatment arms; levels of the latter were lower in patients treated with liraglutide and metformin. Serum alanine aminotransferase concentrations decreased in all treatment arms, whereas serum aspartate aminotransferase concentrations were reduced only by liraglutide and metformin. In all patients, weight loss and total, trunk, limb, and android fat mass reductions were positively correlated with decreases in serum alanine aminotransferase and aspartate aminotransferase levels, whereas reductions in waist circumference were positively correlated with lower serum alanine aminotransferase levels. Conclusions: Compared with gliclazide, liraglutide and metformin monotherapies result in greater weight loss, reductions in body fat mass, and better blood glucose control among type 2 diabetes mellitus patients with non‐alcoholic fatty liver disease. Reductions in weight, fat mass and waist circumference favorably affect hepatic function.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/jdi.12888

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Research works printed but not linked: 18

  1. 10.2337/dc18-S008 · DOI · Paper page
  2. 10.1002/oby.21654 · DOI · Paper page
  3. 10.1111/j.1463-1326.2006.00686.x · DOI · Paper page
  4. 10.1186/1475-2840-13-36 · DOI · Paper page
  5. 10.1007/s00592-014-0638-3 · DOI
  6. 10.1016/j.jacc.2013.06.027 · DOI · Paper page
  7. 10.1210/jc.2004-1579 · DOI · Paper page
  8. 10.2337/dc12-2534 · DOI
  9. 10.1016/j.diabres.2015.04.008 · DOI
  10. 10.1210/jc.2013-2920 · DOI
  11. 10.1002/dmrr.2470 · DOI · Paper page
  12. 10.1111/1753-0407.12555 · DOI · Paper page
  13. 10.1007/s00125-014-3302-0 · DOI
  14. Rondanelli M, 2016, Twenty‐four‐week effects of liraglutide on body composition, adherence to appetite, and lipid profile in overweight and obese patients with type 2 diabetes mellitus, Patient Prefer Adherence, 10, 407
  15. 10.1016/j.curtheres.2013.10.002 · DOI
  16. 10.1111/dom.13190 · DOI
  17. 10.1111/j.1464-5491.2004.01426.x · DOI · Paper page
  18. 10.1080/00325481.2016.1169894 · DOI · Paper page

Cited by

Metadata

Authors
Feng, W., Bi, Y., Li, P., Yin, T., Gao, C., Shen, S., Gao, L., Yang, D., & Zhu, D.
Venue
Journal of Diabetes Investigation
Publisher
Wiley
Published
2018-08-16
Volume
10
Issue
2
Pages
399-407
ISSN
  • 2040-1116 (ISSN-L)
  • 2040-1124
OpenAlex
W2810643620
Cited by
139
References
18
FWCI
7.33
Type
journal article
Language
en
Open access
gold
Funders
  • National Natural Science Foundation of China (81570737, 81570736, 81370947)
  • Nanjing University (14380296)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.